Sign inJoin
Company / Finance

Adagene Inc.

ADAG · NASDAQ

Adagene is trying to turn SAFEbody antibody masking into a broader immuno-oncology platform. The hook is muzastotug's early dose-dependent signal; the catch is that randomized proof, partner execution, and financing still decide the stock.

FollowAdd to WatchlistAsk Question
NASDAQADAGCoverage BootstrapBiotechnologyOncologyImmuno-Oncology
Latest ReportMay 14, 2026Adagene: the masked-antibody bet trying to outrun dilutionView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->
Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.

Sign in as admin